Get the Stockscreener App
6.14
18.76%
0.97
Bioage Labs Inc stock is traded at $6.14, with a volume of 4.21M.
It is up +18.76% in the last 24 hours and down -66.63% over the past month.
Bioage Labs Inc is a clinical-stage biopharmaceutical company developing therapeutic product candidates for metabolic diseases, such as obesity, by targeting the biology of human aging. Its focus is metabolic disease, one of the greatest healthcare challenges. Its Products are Azelaprag (BGE-105), an apelin receptor APJ agonist that increases weight loss and improves body composition combined with incretin drugs. and BGE-100 is targeting metabolic diseases and neuroinflammation.
See More
Previous Close:
$5.17
Open:
$5.1
24h Volume:
4.21M
Relative Volume:
6.52
Market Cap:
$220.11M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+43.46%
1M Performance:
-66.63%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$5.0101
$6.74
1-Week Range:
$3.85
$6.74
52-Week Range:
$3.85
$26.62
Bioage Labs Inc Stock (BIOA) Company Profile
Name
Bioage Labs Inc
Sector
Phone
510-806-1445
Address
1445A SOUTH 50TH STREET, RICHMOND
Compare BIOA with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BIOA
Bioage Labs Inc
|
6.14 | 220.11M | 0 | 0 | 0 | 0.00 |
|
ZTS
Zoetis Inc
|
164.84 | 74.37B | 9.15B | 2.43B | 2.31B | 5.32 |
|
HLN
Haleon Plc Adr
|
9.69 | 43.81B | 14.26B | 1.55B | 0 | 0.3383 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.10 | 41.53B | 30.27B | 1.93B | 3.45B | 0.6044 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
22.09 | 25.03B | 16.77B | -959.00M | 1.37B | -0.85 |
|
VTRS
Viatris Inc
|
12.52 | 14.94B | 15.05B | -883.30M | 1.89B | -0.74 |
Bioage Labs Inc Stock (BIOA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-09-24 | Downgrade | Citigroup | Buy → Neutral |
| Dec-09-24 | Downgrade | Jefferies | Buy → Hold |
| Oct-21-24 | Initiated | Citigroup | Buy |
| Oct-21-24 | Initiated | Jefferies | Buy |
| Oct-21-24 | Initiated | Morgan Stanley | Overweight |
View All
Bioage Labs Inc Stock (BIOA) Latest News
BioAge Labs, Inc. (BIOA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
Hunterbrook Capital long Bioage Labs, Hunterbrook Media reports - TipRanks
BioAge Labs snags potential half-billion-dollar research deal with NovartisBizwomen - The Business Journals
Aging-focused drug company lands new partner, potential half-billion-dollar payout - The Business Journals
BioAge Labs (BIOA) Azelaprag Trial Halt Raises Questions About Pre-IPO Disclosures – Hagens Berman - GlobeNewswire
BIOA SHAREHOLDER REPORT: BioAge Labs Investors are Notified the Company is Being Investigated and are Urged to Contact BFA Law - Newsfile
BioAge and Novartis seek drug targets for ageing-related diseases - Yahoo Finance
BioAge, Novartis team up to discover age-related disease targets - MSN
East Bay aging-focused drug company lands new partner, potential half-billion-dollar payout - The Business Journals
BioAge Labs Announces Multi-Year Collaboration with Novartis - Lifespan.io News
BioAge Labs inks $500 million+ collaboration with Novartis - The Pharma Letter
Bioage Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies That Address Age-Related Diseases and Conditions - Marketscreener.com
BioAge Stock Advances 14% On Novartis Research Collaboration - Marketscreener.com
BioAge, Novartis partner on aging-related drug targets - Investing.com
BioAge Labs Announces Multi-Year Collaboration with Novartis to Discover Novel Targets for Therapies that Address Age-Related Diseases and Conditions - The Manila Times
BIOA SHAREHOLDER NOTICE: BioAge Labs Investors are Alerted - GlobeNewswire
BIOAGE ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
Kirby McInerney LLP Announces Investigation Against BioAge Labs, Inc. (BIOA) on Behalf of Investors - GlobeNewswire
BIOA INVESTOR NOTICE: BioAge Labs is being Investigated - GlobeNewswire
BIOA INVESTOR NOTICE: BioAge Labs is being Investigated after Discontinuing its Phase 2 Trials -- Contact BFA - EIN News
BIOA INVESTOR ALERT: BioAge Labs Investors are Alerted of Ongoing Investigation into the 76% Stock Drop and are Encouraged to Contact BFA Law - Newsfile
BIOA SHAREHOLDER NOTICE: BioAge Labs is Under Investigation - GlobeNewswire
BIOA SHAREHOLDER NOTICE: BioAge Labs is Under Investigation after the 76% Stock Drop – Contact BFA Law if You Lost Money (NASDAQ:BIOA) - GlobeNewswire Inc.
BIOA SHAREHOLDER NEWS: BioAge Labs, Inc. Investors are Notified of the Ongoing Investigation into the Discontinuation of the Phase 2 Trials – Contact BFA Law - AccessWire
Bronstein, Gewirtz & Grossman, LLC Is Investigating BioAge Labs, Inc. (BIOA) And Encourages Stockholders to Connect - AccessWire
BIOA SHAREHOLDER ALERT: BFA Law Notifies BioAge Labs, Inc. Investors to Contact the Firm about its Ongoing Investigation - Newsfile
BioAge Labs, Inc. (BIOA) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - AccessWire
BIOA INVESTIGATION ALERT: BFA Law Alerts BioAge Labs, Inc. - GlobeNewswire
Biotech Stock Roundup: BIOA Down on Study Update, QURE, CRDF Gain on Study Data & More - MSN
SHAREHOLDER ALERT: Investigation of BioAge Labs, Inc. (BIOA) Announced by Holzer & Holzer, LLC - GlobeNewswire
BIOA INVESTIGATION: BFA Law Notifies BioAge Labs, Inc. Investors that it is Investigating the Company after the Stock Plummeted 76% and Urges You to Contact the Firm - Newsfile
BioAge Labs stock faces downgrade with no major data expected until 2026 By Investing.com - Investing.com South Africa
BIOA BREAKING NEWS: BFA Law Announces an Investigation into - GlobeNewswire
BIOA Investors Have Opportunity to Join BioAge Labs, Inc. Securities Fraud Investigation with the Schall Law Firm - PR Newswire
BioAge Labs, Inc. ALERT: Securities Fraud Investigation by Block & Leviton Could Allow ... - The Bakersfield Californian
BioAge Labs, Inc. ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover Losses - GlobeNewswire
BioAge Labs, Inc. ALERT: Securities Fraud Investigation by Block & Leviton Could Allow Investors to Recover - EIN News
BioAge Labs stock faces downgrade with no major data expected until 2026 - Investing.com Australia
Jefferies Downgrades BioAge Labs (BIOA) - MSN
Citigroup Downgrades BioAge Labs (BIOA) - MSN
BioAge Labs craters after dropping clinical study on top drug candidate for obesity - Mugglehead
BioAge stock downgraded: Citi sees limited upside after trial discontinuation By Investing.com - Investing.com Australia
BioAge halts obesity trial after safety concerns - Longevity.Technology
BioAge’s Hopes For Combo Obesity Drug Dim Due To Liver Safety - Citeline News & Insights
Richmond-based BioAge sees stock fall over 70% after halting obesity drug clinical trial - The Business Journals
Crude Oil Gains 2%; BioAge Labs Shares Plunge - Inkl
Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday - Benzinga
BioAge Labs stock under pressure after Phase II trial termination, says Jefferies - Investing.com India
BioAge halts ongoing Phase II trial of obesity drug due to liver concerns - Yahoo Finance
BioAge's chances slimmer after obesity failure - The Pharma Letter
BioAge Labs, Riot Platforms And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga
Bioage Labs Inc Stock (BIOA) Financials Data
There is no financial data for Bioage Labs Inc (BIOA). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Bioage Labs Inc Stock (BIOA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Pande Vijay Satyanand | Director |
Oct 02 '24 |
Buy |
19.73 |
67,096 |
1,323,804 |
1,093,889 |
| Pande Vijay Satyanand | Director |
Oct 03 '24 |
Buy |
19.90 |
25,306 |
503,589 |
1,119,195 |
| Cormorant Asset Management, LP | Former 10% Owner |
Sep 27 '24 |
Buy |
18.00 |
450,000 |
8,100,000 |
1,629,529 |
| Pande Vijay Satyanand | Director |
Sep 27 '24 |
Buy |
18.00 |
900,000 |
16,200,000 |
900,000 |
| ENRIGHT PATRICK G | Director |
Sep 27 '24 |
Buy |
18.00 |
400,000 |
7,200,000 |
1,710,589 |
| HEALY JAMES | Director |
Sep 27 '24 |
Buy |
18.00 |
666,665 |
11,999,970 |
2,227,124 |
1.61%
1.65%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):